Biggest News Aggregation in the World
📰 Patrick Lin News

Page 3 - Patrick Lin News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Patrick Lin. Real-time updates on events, politics, business and more.

UBS AG FI Enhanced Global High Yield ETN (NYSEARCA:FIHD) Stock Price Down 1.5%

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) shares shot up 2.6% during mid-day trading on Tuesday . The company traded as high as $0.57 and last traded at $0.56. 35,908 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 201,922 shares. The stock had previously closed at $0.55. […]
David Young Patrick Lin News Ratings For Processa Pharmaceuticals Daily Raymond James Financial Services Advisors Inc Processa Pharmaceuticals Company Profile Processa Pharmaceuticals

Processa Pharmaceuticals (NASDAQ:PCSA) Shares Down 2.8%

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) shares traded down 2.8% during trading on Monday . The stock traded as low as $0.62 and last traded at $0.70. 177,993 shares traded hands during mid-day trading, a decline of 22% from the average session volume of 227,829 shares. The stock had previously closed at $0.72. Analyst […]
Patrick Lin David Young Renaissance Technologies Processa Pharmaceuticals Inc News Ratings For Processa Pharmaceuticals Daily Maxim Group

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Short Interest Update

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) was the recipient of a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 186,400 shares, a drop of 41.7% from the March 15th total of 319,700 shares. Based on an average daily volume of 274,600 shares, the […]
Patrick Lin David Young Processa Pharmaceuticals Institutional Trading Of Processa Pharmaceuticals News Ratings For Processa Pharmaceuticals Daily Processa Pharmaceuticals Inc

Processa Pharmaceuticals (NASDAQ:PCSA) Price Target Cut to $4.00 by Analysts at Benchmark

Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) had its price target decreased by Benchmark from $9.00 to $4.00 in a research report released on Tuesday morning, Benzinga reports. Benchmark currently has a speculative buy rating on the stock. A number of other analysts have also recently issued reports on PCSA. Oppenheimer cut their price objective on […]
Patrick Lin David Young Processa Pharmaceuticals Maxim Group Renaissance Technologies Dimensional Fund Advisors
Source: wkrb13.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Oppenheimer Lowers Processa Pharmaceuticals (NASDAQ:PCSA) Price Target to $3.00

Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) had its price objective reduced by Oppenheimer from $5.00 to $3.00 in a research note issued to investors on Monday morning, Benzinga reports. They currently have an outperform rating on the stock. Oppenheimer also issued estimates for Processa Pharmaceuticals’ Q1 2023 earnings at ($0.28) EPS, Q2 2023 earnings at […]
Patrick Lin David Young Maxim Group Processa Pharmaceuticals Raymond James Financial Services Advisors Inc Institutional Investors Weigh In On Processa Pharmaceuticals

Oppenheimer Research Analysts Lower Earnings Estimates for Processa Pharmaceuticals, Inc. (NASDAQ:PCSA)

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) – Investment analysts at Oppenheimer decreased their Q1 2023 earnings per share (EPS) estimates for shares of Processa Pharmaceuticals in a research report issued on Monday, April 3rd. Oppenheimer analyst F. Brisebois now anticipates that the company will post earnings of ($0.28) per share for the quarter, down […]
Patrick Lin David Young Maxim Group Processa Pharmaceuticals Processa Pharmaceuticals Price Performance Institutional Investors Weigh In On Processa Pharmaceuticals
Source: wkrb13.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science